Paul Brassil of
Medfield has joined the company as senior vice president/chief information officer and will oversee PCU’s information technology and digital innovation efforts.
Brassil has more than 25 years of experience in the information technology leadership field with entities such as Commonwealth Medicine (a division of UMass Medical School), the Federal Reserve Bank of Boston, EMC Corp. and Siemens IT Solutions and Services Inc.
He holds an MS in computer information systems from Bentley University in
Waltham and a BA in Business Administration from Bridgewater State University.
Brassil s community involvement spans initiatives focused on workforce development and industry leadership serving as a member of the Tech Hire Advisory Group of Boston’s Private Industry Council (comprised of Boston CIOs developing summer intern programs for low/moderate income students in the Boston Public Schools); an adviser for Fintech Women (helping women in banking/finance/fintech a
Editas Medicine
James Mullen takes over as CEO from Feb. 15.
Editas chairman Mullen will don the CEO mantle Feb. 15, taking over for current Editas chief
Cynthia Collins. Before jumping to the Editas team, Mullen was CEO and director of the CDMO Patheon later snapped up by Thermo Fisher and also served as the CEO of Biogen. In a brief release, Editas didn’t say why Collins was leaving. “It has been a privilege to lead Editas Medicine and this extremely talented team,” she said in a statement. “I am particularly proud of the progress to the clinic we have made with both in vivo and ex vivo gene edited medicines.” Collins joined Editas in 2019, picking up the role from
Posted on 256
Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Brian Piekos has been appointed to serve as Chief Financial Officer. Mr. Piekos brings more than 20 years of experience in industry and finance to Gemini.
“It is my pleasure to welcome Brian to the team at this exciting time in Gemini’s history right on the heels of our debut as a public company,” said Jason Meyenburg, Chief Executive Officer of Gemini. “Brian’s deep financial experience and results-driven attitude will be invaluable to us as we continue to develop first-in-class medicines, using insights in genetics and biology, to restore regulation of the complement system in the eye and throughout the body.”